Uniphar plc (UPR) ORD EUR0.08
- Add to watchlist
- Create an alert
- This stock can be held in a
Share news, reports & tips
-
Uniphar reports first-half growth across its divisions
3 September 2024 10:14
(Sharecast News) - International diversified healthcare service provider Uniphar reported a solid set of first-half financial results on Tuesday, with notable growth across all of its divisions.
-
Uniphar flags positive first-half performance
30 July 2024 12:22
(Sharecast News) - Healthcare services business Uniphar announced a positive unaudited trading update for the six months ended 30 June on Tuesday.
-
Uniphar upbeat after successful 2023
9 May 2024 13:11
(Sharecast News) - Uniphar said in an update on Thursday that 2023 was a successful year, as it doubled its 2018 pro-forma EBITDA, ahead of the timeframe it laid out at its initial public offering.
-
Uniphar posts robust set of full-year results
27 February 2024 09:35
(Sharecast News) - Healthcare services company Uniphar reported a robust set of preliminary results on Tuesday, with EBITDA rising 17.7%, as it achieved a return on capital employed of 15.2% and maintained...
-
Uniphar ends year in line with expectations
30 January 2024 12:33
(Sharecast News) - Pharmaceutical and medical technology service company Uniphar said in an update on Tuesday that its performance in 2023 met its own expectations in terms of gross profit and EBITDA, while...
-
Uniphar gross profit jumps in first half
14 September 2023 12:27
(Sharecast News) - Healthcare services company Uniphar reported gross profit growth of 28.6% in its first half on Thursday, of which 5.5% was organic, representing progress across all divisions.
-
Uniphar maintains expectations amid strong trading
11 May 2023 12:19
(Sharecast News) - Uniphar reported strong performance over the last year in an update on Thursday, reporting further progress towards its financial and strategic objectives.
-
Uniphar upbeat on strong full-year performance
28 February 2023 16:14
(Sharecast News) - Healthcare service provider Uniphar reported a strong full-year performance on Tuesday, with EBITDA growth of 13.4%, return on capital employed of 17.3%, and year-end leverage of 1.0x.
-
Irish regulator blocks Uniphar takeover of Navi
16 December 2022 16:21
(Sharecast News) - Uniphar announced on Friday that Ireland's Competition and Consumer Protection Commission (CCPC) had not cleared the proposed acquisition of the Irish-based pharmacy services firm...
-
Uniphar buys BModesto for initial EUR 51m
21 November 2022 10:09
(Sharecast News) - Uniphar announced the €51m acquisition of Netherlands-based healthcare services business BModesto Group on Monday, which works in pharmaceutical and healthcare products access in the...
-
Uniphar buys healthcare consultancy Inspired Health
4 October 2022 09:30
(Sharecast News) - Uniphar announced the acquisition of US-based healthcare insights and intelligence consultancy Inspired Health on Tuesday.
-
Uniphar ends first half in line with expectations
26 July 2022 15:38
(Sharecast News) - Healthcare services company Uniphar said in an update on Tuesday that it performed in line with its expectations in the first half, at both a gross profit and EBITDA level, while...
Company announcements Announcements
-
2024 Interim Results
3 September 2024 07:00
Uniphar (CDI)
-
Half Year Trading Update and Notice of Results
30 July 2024 07:00
Uniphar (CDI)
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2024. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.